期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Preclinical efficacy of a novel cyclin-dependent kinase 9 inhibitor,QHRD107 against acute myeloid leukemia
1
作者 Yan Zhou Hengwen Song +4 位作者 Zhichao Shao bomin yin Ximei Fu Dianyou Xie Lijun Wei 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2021年第2期146-156,共11页
QHRD107 is a specific inhibitor of cyclin-dependent kinase 9(CDK9).It is a highly potent antiproliferative agent against leukemia cells in vitro.Oral administration of QHRD107 to mice bearing acute myeloid leukemia tu... QHRD107 is a specific inhibitor of cyclin-dependent kinase 9(CDK9).It is a highly potent antiproliferative agent against leukemia cells in vitro.Oral administration of QHRD107 to mice bearing acute myeloid leukemia tumors markedly inhibited tumor growth.In Molm-13 orthotopic model,QHRD107 resulted in remarkable prolongation of animal life span.After single oral administration of QHRD107 to Molm-13 xenograft model,QHRD107 was quickly absorbed and distributed to tumor with high concentration within 1 h.Tumor half-life time(T1/2)was three times longer compared with that of plasma.Under the high exposure of QHRD107 in tumor tissue,fast down-regulation of anti-apoptotic protein Mcl-1 mRNA was noted.Reduction of Ki-67 staining in tumor tissue further demonstrated the apoptosis of tumor cells.Therefore,the results provided evidence that QHRD107 at therapeutic dose had significant antitumor activity against AML cell lines. 展开更多
关键词 QHRD107 CDK9 inhibitor EFFICACY PHARMACOKINETICS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部